November 22, 2023 11:01 AM EST

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Syncona scoops up Freeline: British life sciences investor Syncona said Wednesday it agreed to buy gene therapy maker Freeline Therapeutics through …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug

Kyle LaHucik

Senior Reporter

Jaimy Lee

Deputy Editor

Sign up to read this article for free.

Lilly’s oral SERD makes strides in breast cancer with Phase 3 data

The Endpoints 100: The biotech industry braces for Trump 2.0

Exclusive: Bain-backed musculoskeletal biotech raises $120M for trio of clinical-stage biologics

Acelyrin says goodbye to the drug that got it a $540M IPO in 2023

Gene editing companies seek safer, less grueling conditioning methods for blood stem cell therapies

The key to faster, more impactful research? Put patients in the driver’s seat

Syn­cona buys gene ther­a­py com­pa­ny; Ory­zon’s €45M fi­nanc­ing agree­ment; In­Dex scraps PhI­II drug

Senior Reporter

Deputy Editor

Sign up to read this article for free.

Syncona buys gene therapy company; Oryzon’s €45M financing agreement; InDex scraps PhIII drug